Cardiovascular Systems Inc

Cardiovascular Systems — Investor Day (July 2018)

59 slides from Cardiovascular Systems's investor day presentation, Jul 31, 2018

  1. Slide 1: Analyst Day Meeting

    Analyst Day Meeting Scott R. Ward Chairman, President & CEO July 31, 2018

  2. Slide 2: Safe Harbor

    Safe Harbor FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For example, statem

  3. Slide 3: Agenda

    Agenda Overview: Scott Ward Clinician’s Perspective: Dr. Martin Leon Driving Sustainable Long-Term Growth: Rhonda Robb Clinician’s Perspective: Dr. David Kandzari Growth Summary & Financial Performance: Jeff Points Closing Comments: Scott Ward Physician Q&A: Dr. Martin Leon and Dr. David Kandzari CS

  4. Slide 4: Cardiovascular Systems, Inc. Overview

    Cardiovascular Systems, Inc. Overview Historical Revenue Highly Differentiated and Proprietary Core Technology $300 10% 3-Year CAGR Serving Large and Growing Markets $250 $217 $205 $200 $178 Complex and Difficult Disease State $150 Robust Medical Evidence (Millions) $100 Large and Established U.S. S

  5. Slide 5: Commitment to Our Mission

    Commitment to Our Mission Saving Limbs, Saving Lives Every Day Focused on Complex Peripheral and Coronary Artery Disease 2 Million+ 160,000 370,000 525,000 Deaths Annually From High Risk or Complex Patients with Critical Annual Amputations Coronary Artery High Risk Procedures Limb Ischemia (CLI)1 in

  6. Slide 6: Experienced and Talented Team

    Experienced and Talented Team Average Experience in Medical Technology: 18 Years Scott R. Ward, MS, MBA Jeffrey S. Points, MBA, Rhonda J. Robb, MBA Chairman, CPA Chief Operating Officer President and CEO Chief Financial Officer Alexander Rosenstein, Ryan D. Egeland, MD David S. Whitescarver, JD PhD

  7. Slide 7: CSI Today

    CSI Today # 1 67 K >700 80 Market leadership 227 Patients treated of Mission Driven Engineers in calcified peripheral & Patents annually Employees and Scientists coronary atherectomy FY18 8% 68% Other Peripheral OAS $217M In Revenue 1% 23% International Coronary OAS

  8. Slide 8: Strong Financial Platform for Growth

    Strong Financial Platform for Growth Profitable Business Model: FY18 Net Income $1.7M Revenues Gross Margin Adjusted EBITDA Cash Balance 10% +80% +$56M +$56M CAGR $16.5M $217M $12.9M $205M 82% $116.3M $107.9M $178M 81% FY16 FY17 FY18 $60.6M 80% $(39.2)M FY16 FY17 FY18 FY16 FY17 FY18 FY16 FY17 FY18

  9. Slide 9: Driving Sustainable Growth: Broaden Our Value Streams

    Driving Sustainable Growth: Broaden Our Value Streams • Financial Goal: Five Year CAGR of 15 - 18% and Revenue of $435M - $500M in FY23 Financial Strength and the Talent to Execute Grow and Protect the Core Business Growth, Profitability, Cash and Liquidity Sustain Market Leadership Experienced and

  10. Slide 10: Appendix: Non-GAAP Financial Measures

    Appendix: Non-GAAP Financial Measures To supplement CSI's consolidated condensed financial statements prepared in accordance with GAAP, CSI uses a non-GAAP financial measure referred to as "Adjusted EBITDA" in this presentation. Reconciliations of this non-GAAP measure to the most comparable U.S. GA

  11. Slide 11: Appendix: Non-GAAP Financial Measures

    Appendix: Non-GAAP Financial Measures The following is an explanation of each of the items that management excluded from Adjusted EBITDA and the reasons for excluding each of these individual items: -- Stock-based compensation. CSI excludes stock-based compensation expense from its non-GAAP financia

  12. Slide 12: Driving Sustainable, Long-Term Growth

    Driving Sustainable, Long-Term Growth Rhonda Robb Chief Operating Officer July 31, 2018

  13. Slide 13: Safe Harbor

    Safe Harbor FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For example, statem

  14. Slide 14: Key Growth Drivers

    Key Growth Drivers Core Business New Geographies Innovation Achieve $435M - $500M in Revenue in FY23 (15% - 18% CAGR)

  15. Slide 15: CSI Will Remain Focused on Complex Coronary and Peripheral Disease

    CSI Will Remain Focused Complex Coronary and Peripheral Disease Large, and growing markets with significant unmet medical needs Aging Patient Populations CSI market leadership with OAS in peripheral and coronary segments Opportunities for Innovation Focused on Complex Peripheral and Coronary Artery

  16. Slide 16: Key Growth Drivers: Core Business

    Key Growth Drivers Innovation in product line extensions Site of service strategies Evidence Core Business Expertise Excellence in quality and manufacturing Sustain 10+ % Growth in our Core Business

  17. Slide 17: Innovation: Ease of Use with OAS Enhancements

    Innovation Ease of Use with OAS Enhancements GlideAssist is an innovative solution that: • Facilitates device tracking • Provides easier device repositioning • Exceptional performance especially in challenging anatomies ViperWire Flex Tip and Next Generation Pump launching in FY19 Video with represe

  18. Slide 18: Innovation: Radial is a Core Competitive Advantage

    Innovation Radial is a Core Competitive Advantage A new differentiated route of access for CSI, complementary to tibial/pedal Diamondback low 5Fr profile, with extended working length enables unique radial approach Expansion in portfolio of radial support devices: wires, sheaths, catheters, PTA ball

  19. Slide 19: Innovation: Complete Revascularization Differentiators

    Innovation Complete Revascularization Differentiators Maximize Sales Productivity Broader portfolio to treat more patients with Interventional Support Products with small and larger vessels Sapphire balloons, 1.0mm specialty balloons New 1.0mm solution for sub- and chronic total occlusions Microcath

  20. Slide 20: Innovation: Peripheral Exchangeable Platform

    Innovation Complete Revascularization Differentiators Peripheral Exchangeable Platform Up to 50% of peripheral patients have multi-level disease Innovation facilitates utilization of multiple crowns during a single case Patient and economic benefits Business model innovation may enable new product c

  21. Slide 21: Site of Service Strategies

    Site of Service Strategies Customer Focused and Targeted to Drive Share/Volume Peripheral Peripheral Coronary Hospital Office Based Lab Dedicated coronary reps and Adaptive sales model given support needs, clinical specialists clinical specialists Educational excellence Long-term contracts with pric

  22. Slide 22: Leadership in Clinical Evidence

    Leadership in Clinical Evidence 5000+ 7000 600 Patients Lesions Physicians Trial Size Importance • “All-comers” trial vs. any other treatment LIBERTY 360° (Enrollment Complete) n=1,204 • Nearly 700 Rutherford Class 4-6 patients enrolled • OAS + DCB vs. DCB alone PAD OPTIMIZE (Enrollment Complete) n=

  23. Slide 23: Leadership in Medical Evidence: ECLIPSE

    Leadership in Medical Evidence ECLIPSE Will Drive OAS as Standard of Care for Vessel Preparation Trial designed to establish a new standard of care of vessel preparation for patients with complex coronary disease Enrolling 2000 patients, 100 sites 400+ enrollments to date Enrollment completion expec

  24. Slide 24: Medical Evidence: Peripheral Evidence Driving Guidelines

    Medical Evidence Peripheral Evidence Driving Guidelines 2016 AHA/ACC Guidelines on the 2 Year Clinical Data Presented; Management of Patients with PAD1 AMP August 8, 2018 Economic Data Presented FY19 Initiating 500 patient BTK An evaluation for revascularization study in 2019 options should be perfo

  25. Slide 25: Excellence in Quality and Manufacturing

    Excellence in Quality and Manufacturing Scalable and Continuous COGS Reductions Manufacturing Volume driven overhead leverage Initiatives Labor productivity Scalable and continuous reductions LEAN continuous improvement protect margins from likely ASP declines Material cost reductions Sourcing and o

  26. Slide 26: Key Growth Drivers: New Geographies

    Key Growth Drivers Japan Launch Expanding Steady Cadence New Geographies Progressing Well Global Distribution of New Product Network Introductions New Geographies to Provide $25M-$50M in Revenue in FY23

  27. Slide 27: Japan Launch Progressing Well

    Japan Launch Progressing Well Japan launch is progressing on plan Calcific burden in Japan significant Physicians accept need/value of vessel preparation Medikit is the exclusive distribution partner in Japan Coronary Classic and ViperWire Flex launch early 2019 Initiate enrollment of Peripheral OAS

  28. Slide 28: Expand Global Distribution Network

    Expand Global Distribution Network

  29. Slide 29: Expand Global Distribution Network

    Expand Global Distribution Network Global interventional solutions provider Leadership team and distribution strength Footprint in more than 60 countries and Immediate CSI access to key markets across six continents Strong customer relationships; reputation Focus and ability to leverage infrastructu

  30. Slide 30: A Steady Cadence of New Geographies

    A Steady Cadence of New Geographies FY19 FY23 $25M-$50M in FY23 FY19 FY23 Japan $25M - $50M Europe Middle East Southeast Asia $15M - $17.5M Canada $1.8M China FY18 FY21 FY23 Coronary Peripheral

  31. Slide 31: Key Growth Drivers: Innovation

    Key Growth Drivers Innovation drives long term growth potential 20 new product launches by FY23 Portfolio expansion into complex Innovation coronary and peripheral patients $70M-$100M in Revenue From New Products in FY23

  32. Slide 32: Building a Cardiovascular Company: Steady Cadence of Product Launches

    Building a Cardiovascular Company Steady Cadence of 20 Product Launches Through FY23 Innovation Will Drive $70M-$100M in Revenue in Fiscal 2023 Platforms Peripheral Products Coronary Products Support Products ViperWire Flex Laser Mixed Plaque Atherectomy Atherectomy OAS Gen III Scoring Balloons cPCI

  33. Slide 33: Unmet Needs Shape our Innovation Strategy: Complex Coronary Patient

    Unmet Needs Shape our Innovation Strategy Complex Coronary Patient 16-18 Million Coronary Artery Disease1 ~1.2 Million Annual CAD Interventions (PCI or CABG)2 880k PCI3 525k Complex4 ~150k-200k Core OAS cPCI* PCI Support CTO/STO In Stent High Risk Innovations – Hemodynamic 4 Products Products Resten

  34. Slide 34: CSI cPCI Hemodynamic Support

    CSI cPCI Hemodynamic Support Video with representation of proposed product

  35. Slide 35: Unmet Needs Shape Our Innovation: Complex Peripheral Patient

    Unmet Needs Shape Our Innovation Complex Peripheral Patient 20 Million Peripheral Arterial Disease1 ~5.7 Million CSI Strategic Approach Diagnosed Critical Limb Ischemia or Intermittent Claudicant 2 CSI will provide a full product line to serve patients with varying degrees of 900k PAD burden Annual

  36. Slide 36: Future Innovation: Vessel Preparation for Mixed Plaque

    Future Innovation Vessel Preparation for Mixed Plaque CSI and Aerolase Corp. Development Agreement Laser Atherectomy Catheter Treats Soft Plaque and ISR

  37. Slide 37: Future Innovation: Vessel Preparation for Soft Plaque/ISR

    Future Innovation Vessel Preparation for Soft Plaque/ISR Large and attractive market, complimentary to OAS; expands the patient population that CSI will serve in a segment lacking innovation Target patients: De novo soft plaque and ISR in the peripheral patients; expand to Coronary Leverage existing

  38. Slide 38: Driving Sustainable Long-Term Growth: Key Value Drivers and Milestones

    Driving Sustainable Long-Term Growth Key Value Drivers Key Milestones Future Revenue 2019-2020 5 - Year CAGR 15% – 18% $435M - $500M • ViperWire, Next Gen Pump• PCI Support Portfolio • Radial Support Portfolio • Japan, Europe, Middle East, Asia • Peripheral Exchangeable $300M - $350M 2021-2022 $240M

  39. Slide 39: Driving Sustainable Growth: Broaden Our Value Streams

    Driving Sustainable Growth: Broaden Our Value Streams Financial Goal: Five Year CAGR of 15% - 18% & Revenue of $435M - $500M in FY23 Financial Strength and the Talent to Execute Grow and Protect the Core Business Growth, Profitability, Cash and Liquidity Sustain Market Leadership Experienced and Tal

  40. Slide 40: Appendix: Non-GAAP Financial Measures

    Appendix: Non-GAAP Financial Measures To supplement CSI's consolidated condensed financial statements prepared in accordance with GAAP, CSI uses a non-GAAP financial measure referred to as "Adjusted EBITDA" in this presentation. Reconciliations of this non-GAAP measure to the most comparable U.S. GA

  41. Slide 41: Appendix: Non-GAAP Financial Measures

    Appendix: Non-GAAP Financial Measures The following is an explanation of each of the items that management excluded from Adjusted EBITDA and the reasons for excluding each of these individual items: -- Stock-based compensation. CSI excludes stock-based compensation expense from its non-GAAP financia

  42. Slide 42: Growth Summary and Financial Performance

    Growth Summary and Financial Performance Jeff Points Chief Financial Officer July 31, 2018

  43. Slide 43: Safe Harbor

    Safe Harbor FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For example, statem

  44. Slide 44: Strong and Stable Business Model

    Strong and Stable Business Model Cash and Liquidity $116M in cash and cash equivalents Recurring cash flow $40M line of credit at June 30, 2018 generated from operations unused and available Revenue Adjusted EBITDA Gross Margin (Millions) (Millions) CAGR = 12% $217 $16 82% $205 $13 81% $182 $178 80%

  45. Slide 45: Platform for Growth

    Platform for Growth Growth through geographic expansion and innovation Organic growth investments are internally funded ~$250M R&D investments increase to 14%-17% FY19-FY23 R&D Investments of revenues in FY21 (12% in FY18) Leveraging SG&A spend down as a % of revenue Opportunistic portfolio manageme

  46. Slide 46: Broadening Value Streams

    Broadening Value Streams International and New Products account for approximately 24% of total revenues in FY23 1% 76% 5% 7% FY18 7% FY21 88% FY23 99% 17% OAS Base New Products International

  47. Slide 47: FY21 Financial Goals

    FY21 Financial Goals CSI Cost Down Material Cost Reduction Programs Volume Driven OH Leverage LEAN Productivity Initiatives Revenues Gross Margins R&D Investments Adjusted EBITDA Net Income • $300M–$350M • 78%–80% • Approximately $50M • 8%–10% • 3%–5% • CAGR = 11%-17% • Ongoing cost (14%-17% of reve

  48. Slide 48: Poised for Significant Long-Term Revenue Growth

    Poised for Significant Long-Term Revenue Growth Historical Revenue Future Revenue $435M–$500M $300M–$350M $240M–$250M $217M $205M $182M $178M $137M FY14 FY15 FY16 FY17 FY18 FY19 FY21 FY23 12% 15%–18% CAGR 5-Year CAGR

  49. Slide 49: Appendix: Non-GAAP Financial Measures

    Appendix: Non-GAAP Financial Measures To supplement CSI's consolidated condensed financial statements prepared in accordance with GAAP, CSI uses a non-GAAP financial measure referred to as "Adjusted EBITDA" in this presentation. Reconciliations of this non-GAAP measure to the most comparable U.S. GA

  50. Slide 50: Appendix: Non-GAAP Financial Measures

    Appendix: Non-GAAP Financial Measures The following is an explanation of each of the items that management excluded from Adjusted EBITDA and the reasons for excluding each of these individual items: -- Stock-based compensation. CSI excludes stock-based compensation expense from its non-GAAP financia

  51. Slide 51: Analyst Day Meeting

    Analyst Day Meeting Scott R. Ward Chairman, President & CEO July 31, 2018

  52. Slide 52: Safe Harbor

    Safe Harbor FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For examples, state

  53. Slide 53: Creating Shareholder Value

    Cardiovascular Systems, Inc. Creating Shareholder Value Leveraging a A Compelling Creating Competitive Financially Strong with the Strong Core Business Growth Strategy Advantage Team and Talent to Win Improving outcomes for Driving market leading Highest quality Sustaining double digit growth comple

  54. Slide 54: David E. Kandzari, MD

    David E. Kandzari, MD Director of Interventional Cardiology and Chief Scientific Officer Piedmont Heart Institute Dr. David E. Kandzari is the Director, Interventional Cardiology of the Piedmont Heart Institute and Chief Scientific Officer for the Piedmont Healthcare in Atlanta, Georgia. Dr. Kandzar

  55. Slide 55: Martin B. Leon, MD

    Martin B. Leon, MD Director, Center for Interventional Vascular Therapy Columbia University Medical Center Martin B. Leon, MD, is a Professor of Medicine at Columbia University College of Physicians and Surgeons and Director of the Center for Interventional Vascular Therapy (CIVT) at NewYork-Presbyt

  56. Slide 56: Jeffrey S. Points, Chief Financial Officer

    Jeffrey S. Points Chief Financial Officer Cardiovascular Systems, Inc. Mr. Points joined CSI in September 2007 as Corporate Controller, became Senior Director and Controller in July 2013, Corporate Controller and Treasurer in January 2015, Vice President, Corporate Controller and Treasurer in May 20

  57. Slide 57: Rhonda J. Robb, Chief Operating Officer

    Rhonda J. Robb Chief Operating Officer Cardiovascular Systems, Inc. Ms. Robb joined CSI as Chief Operating Officer in January 2018. Ms. Robb brings more than 30 years of medical device leadership to the company. Prior to CSI, she held several positions at Medtronic, most recently as Vice President a

  58. Slide 58: Scott R. Ward, Chairman, President & CEO

    Scott R. Ward Chairman, President & Chief Executive Officer Cardiovascular Systems, Inc. Mr. Ward has been a member of the CSI Board of Directors since 2013 and has served as Chairman since November 2014. Mr. Ward served as our Interim President and Chief Executive Officer commencing in November 201

  59. Slide 59: Trademarks

    CSI®, Diamondback®, Diamondback 360®, GlideAssist®, ViperWire® and ViperWire Advance® are trademarks of Cardiovascular Systems, Inc. © 2018 Cardiovascular Systems, Inc. Sapphire® and OrbusNeich® are trademarks of OrbusNeich Medical, Inc.

Cardiovascular Systems — Investor Day (July 2018) on 6ix